

# Preadmission Statin Treatment and Outcome in Patients Hospitalized With COVID-19



Marwan Saad, MD, PhD<sup>a,b</sup>, Kevin F. Kennedy, MS<sup>a</sup>, David W. Louis, MD<sup>a,b</sup>, Hafiz Imran, MD<sup>a,b</sup>, Charles F. Sherrod, IV, MD<sup>c</sup>, Karen Aspry, MD<sup>a,b</sup>, Amgad Mentias, MD, MPH<sup>b</sup>, Athena Poppas, MD<sup>a,b</sup>, J. Dawn Abbott, MD<sup>a,b</sup>, and Herbert D. Aronow, MD, MPH<sup>a,b,\*</sup>

**Preadmission statin therapy is associated with improved outcome in patients hospitalized with COVID-19. Whether inhibition of inflammation and myocardial injury are in part responsible for this observation has not been studied. The aim of the present study was to relate preadmission statin usage to markers of inflammation, myocardial injury, and clinical outcome among patients with established atherosclerosis who were admitted with COVID-19. Adult patients with a diagnosis of coronary artery disease, peripheral artery disease, and/or atherosclerotic cerebrovascular disease who were hospitalized with COVID-19 between March 1, 2020 and December 31, 2020 were included. Statin use was related to the primary composite clinical outcome, death, intensive care unit admission, or thrombotic complications in sequential multivariable logistic regression models. Of 3,584 adult patients who were hospitalized with COVID-19, 1,360 patients met study inclusion criteria (mean age 73.8 years, 45% women, 68% White). Baseline troponin and C-reactive protein were lower in patients on statins before admission. In an unadjusted model, preadmission statin usage was associated with a significant reduction in the primary composite outcome (42.2% vs 53.7%, odds ratio 0.63 [95% confidence interval 0.50 to 0.80],  $p < 0.001$ ). This association remained significant after age, gender, ethnicity, other patient clinical characteristics, and cardiovascular medications were added to the model but became null when troponin and C-reactive protein were also included (odds ratio 0.83 [95% confidence interval 0.63 to 1.09]  $p = 0.18$ ). In conclusion, among patients with established cardiovascular disease who were hospitalized with COVID-19, preadmission statin therapy was associated with improved in-hospital outcome, an association that was negated once inflammation and myocardial injury were considered. © 2022 Elsevier Inc. All rights reserved. (Am J Cardiol 2022;177:28–33)**

COVID-19, caused by SARS-CoV-2, has been associated with significant morbidity and mortality, mainly mediated through an intense inflammatory host response with resultant respiratory and multiorgan failure.<sup>1</sup> Elevation of biomarkers, reflecting inflammation and myocardial injury, predict poorer outcome in patients with COVID-19.<sup>2–4</sup> Statins possess antiviral, immunomodulatory, antithrombotic, and anti-inflammatory properties<sup>5</sup> and reduce inflammation and myocardial injury in patients with atherosclerotic vascular disease,<sup>6</sup> properties which may translate into improved short- and long-term outcomes in these patients.<sup>7,8</sup> Observational studies of patients hospitalized with COVID-19 have found that preadmission statin use is associated with less inflammation, less severe disease manifestations, and improved outcomes;<sup>9,10</sup> whether statins reduce myocardial injury in this setting is unknown. The present study examined whether markers of inflammation and myocardial injury modify the relation

between preadmission statin use and clinical outcome in patients hospitalized with COVID-19.

## Methods

Baseline demographic, clinical, medication, laboratory, and outcome data were extracted electronically from the EPIC Systems electronic health record. All consecutive patients aged  $\geq 18$  years, with a diagnosis of coronary artery disease, peripheral artery disease, and/or atherosclerotic cerebrovascular disease who were hospitalized with COVID-19 at Rhode Island, the Miriam or Newport Hospitals, between March 1, 2020 and December 31, 2020 were included. Co-morbidities, COVID-19 status, and in-hospital outcomes were ascertained using International Classification of Diseases, Tenth Revision codes (Supplementary Material). Approval and waiver of informed consent were granted by the Miriam Hospital Institutional Review Board.

Statin use was ascertained from home and inpatient medication lists. Statins were categorized by agent, dose, intensity,<sup>11</sup> and solubility. If 2 statins were listed, the higher intensity statin took precedence and was included in the descriptive table; patients in whom both a lipophilic and hydrophilic statin were listed were excluded from the descriptive statistics on statin solubility.

<sup>a</sup>Lifespan Cardiovascular Institute, Providence, Rhode Island; <sup>b</sup>Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island; and <sup>c</sup>Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, Ohio. Manuscript received February 5, 2022; revised manuscript received and accepted April 15, 2022.

See page 32 for disclosure information.

\*Corresponding author: Tel: 401-793-4107; fax 401-793-4049.

E-mail address: [herbert.aronow@lifespan.org](mailto:herbert.aronow@lifespan.org) (H.D. Aronow).




Figure 1. Study flowchart. CAD = coronary artery disease; CVD = cerebrovascular disease; PAD = peripheral artery disease.

The primary composite outcome included in-hospital death, intensive care unit (ICU) admission, or composite thrombotic complications. Secondary clinical outcomes included individual components of the primary composite outcome, composite death or ICU admission, individual thrombotic complications, and length of stay. Baseline levels of inflammation and myocardial injury were gauged by C-reactive protein (CRP) and cardiac troponin I levels on admission, respectively (Supplementary Material).

Continuous variables are presented as means  $\pm$  SD or medians with interquartile range (IQR) and were compared using the Student *t* test or Wilcoxon rank-sum test, as appropriate. Categorical variables are presented as frequencies and percentages and were compared using the chi-square test.

Preadmission statin use was related to the primary composite clinical outcome in unadjusted and adjusted analyses. Plausible demographic, clinical characteristics, and cardiovascular medications that were related to the primary outcome ( $p \leq 0.15$ ) were eligible for inclusion in multivariable models and are detailed in Supplementary Material. Analyses were performed using sequential multivariable logistic regression models, as follows: (1) unadjusted; (2) model 1 + age, gender, and ethnicity; (3) model 2 + other patient characteristics; (4) model 3 + other cardiovascular medications, and (5) model 4 + CRP and troponin. Patients with missing information regarding preadmission medication use were excluded ( $n = 17$ ). Missing troponin (10%) and CRP (19%) values were imputed using simple imputation techniques (IVEware, Ann Arbor, Michigan). All analyses were performed with SAS 9.4 (SAS Institute, Cary, North Carolina).

## Results

A study flow diagram appears in Figure 1. Of 3,584 adult patients hospitalized with COVID-19, 1,377 had established atherosclerotic cardiovascular disease. The final study cohort comprised 1,360 patients; of these, 1,090 patients (80%) had coronary artery disease, 545 patients

(40%) had cerebrovascular disease, and 31 patients (2%) had peripheral artery disease. Patient characteristics according to preadmission statin use appear in Table 1. Overall mean age was  $73.8 \pm 13.7$  years, 45% were women, and 67.6% were White. Cardiovascular risk factors and risk markers were common. Half of the patients were taking  $\beta$  blockers and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and nearly 2/3 were taking antiplatelet agents before admission.

In the overall cohort, 978 patients (72%) were taking statins before admission (2 statins were listed for 28 of these). Statin use was significantly more common among those with hypertension, diabetes, obesity, previous myocardial infarction (MI) or percutaneous coronary intervention, and among nonsmokers. Atorvastatin was the most commonly used ( $n = 675$ , 69%). Statin use details appear in Table 2 and in Supplementary Material. Of those on preadmission statins, these agents were discontinued during hospitalization in 153 patients (16%); in contrast, of those not on preadmission statins, these agents were initiated in 57 (15.5%) during hospitalization. Patients who were taking statins before admission had lower median (IQR) troponin (0.055 [0.018 to 0.23] vs 0.090 [0.02 to 0.37] ng/ml,  $p = 0.001$ ) and CRP (64.9 [27.0 to 134.3] vs 76.1 [27.0 to 156.0] mg/L,  $p = 0.008$ ) at baseline compared with those not on statins. Patients who were taking high/intermediate-intensity statins before admission had lower median (IQR) troponin (0.051 [0.017 to 0.22] vs 0.086 [0.026 to 0.27] ng/ml,  $p = 0.035$ ) but similar median (IQR) CRP (72.8 [30.7 to 136.7] vs 102.2 [36.0 to 169.9] mg/L,  $p = 0.14$ ) at baseline compared with those not on low-intensity statins.

The primary composite outcome occurred in 618 patients (45%). In an unadjusted analysis, preadmission statin usage was associated with a significantly lower incidence of the primary composite outcome (413 [42.2%] vs 205 [53.7%], odds ratio [OR] 0.63 [95% confidence interval (CI) 0.50 to 0.80],  $p < 0.001$ ). This association remained significant after sequential adjustment (model 2 OR 0.65 [95% CI 0.51 to 0.83],  $p < 0.001$ ; model 3 OR 0.75 [95% CI 0.58 to 0.99],  $p = 0.039$ ; and model 4 OR 0.75 [95% CI

Table 1  
Baseline characteristics

| Variable  | Total (n = 1360)   | Statin therapy     |                    | P-value |
|---|--------------------|--------------------|--------------------|---------|
|   |                    | Yes<br>(n = 978)   | No<br>(n = 382)    |         |
| Age (years), mean $\pm$ SD                      | 73.8 $\pm$ 13.7    | 74.8 $\pm$ 11.7    | 71.3 $\pm$ 17.4    | < 0.001 |
| Female  | 614 (45.1%)        | 432 (44.2%)        | 182 (47.6%)        | 0.25    |
| Hispanic or Latino                              | 233 (17.1%)        | 170 (17.4%)        | 63 (16.5%)         | 0.34    |
| Not Hispanic or Latino                          | 1116 (82.1%)       | 802 (82.0%)        | 314 (82.2%)        |         |
| Unknown   | 1 (0.1%)           | 0 (0.0%)           | 1 (0.3%)           |         |
| White   | 919 (67.6%)        | 665 (68.0%)        | 254 (66.5%)        | 0.66    |
| Asian   | 19 (1.4%)          | 15 (1.5%)          | 4 (1.0%)           |         |
| Black   | 173 (12.7%)        | 119 (12.2%)        | 54 (14.1%)         |         |
| Native Hawaiian/other Pacific Islander          | 3 (0.2%)           | 3 (0.3%)           | 0 (0.0%)           |         |
| Other   | 236 (17.4%)        | 170 (17.4%)        | 66 (17.3%)         |         |
| Unknown   | 10 (0.7%)          | 6 (0.6%)           | 4 (1.0%)           |         |
| Hypertension                                    | 1193 (87.7%)       | 901 (92.1%)        | 292 (76.4%)        | < 0.001 |
| Obesity   | 375 (27.6%)        | 289 (29.6%)        | 86 (22.5%)         | 0.009   |
| Smoker  |                    |                    |                    | < 0.001 |
| Current   | 109 (8.0%)         | 73 (7.5%)          | 36 (9.4%)          |         |
| Former  | 562 (41.3%)        | 454 (46.4%)        | 108 (28.3%)        |         |
| Never   | 528 (38.8%)        | 365 (37.3%)        | 163 (42.7%)        |         |
| Unknown   | 161 (11.8%)        | 86 (8.8%)          | 75 (19.6%)         |         |
| Diabetes mellitus                               | 662 (48.7%)        | 533 (54.5%)        | 129 (33.8%)        | < 0.001 |
| Previous coronary artery disease                | 1088 (80.0%)       | 800 (81.8%)        | 288 (75.4%)        | 0.007   |
| Previous cerebrovascular disease                | 253 (20.8%)        | 177 (20.0%)        | 76 (22.7%)         | 0.31    |
| Previous peripheral artery disease              | 26 (2.1%)          | 18 (2.0%)          | 8 (2.4%)           | 0.70    |
| Previous percutaneous coronary intervention     | 222 (16.3%)        | 197 (20.1%)        | 25 (6.5%)          | < 0.001 |
| Previous coronary artery bypass grafting        | 96 (7.1%)          | 85 (8.7%)          | 11 (2.9%)          | < 0.001 |
| Previous myocardial infarction                  | 312 (22.9%)        | 268 (27.4%)        | 44 (11.5%)         | < 0.001 |
| Previous transient ischemic attack/stroke       | 312 (22.9%)        | 242 (24.7%)        | 70 (18.3%)         | 0.011   |
| Heart failure                                   | 499 (36.7%)        | 376 (38.4%)        | 123 (32.2%)        | 0.031   |
| Valvular heart disease                          | 122 (9.0%)         | 94 (9.6%)          | 28 (7.3%)          | 0.18    |
| Cardiac dysrhythmias                            | 626 (46.0%)        | 458 (46.8%)        | 168 (44.0%)        | 0.34    |
| Chronic kidney disease                          | 355 (26.1%)        | 275 (28.1%)        | 80 (20.9%)         | 0.006   |
| Chronic obstructive pulmonary disorder          | 175 (12.9%)        | 128 (13.1%)        | 47 (12.3%)         | 0.70    |
| Obstructive sleep apnea                         | 155 (11.4%)        | 124 (12.7%)        | 31 (8.1%)          | 0.017   |
| Liver disease                                   | 128 (9.4%)         | 79 (8.1%)          | 43 (11.3%)         | 0.06    |
| Dementia  | 402 (29.6%)        | 275 (28.1%)        | 127 (33.2%)        | 0.06    |
| Cancer  | 151 (11.1%)        | 108 (11.0%)        | 43 (11.3%)         | 0.91    |
| Inflammatory rheumatic disease                  | 200 (14.7%)        | 145 (14.8%)        | 55 (14.4%)         | 0.84    |
| Cardiac troponin, ng/ml, median (IQR)           | 0.065 (0.02, 0.25) | 0.055 (0.02, 0.23) | 0.090 (0.02, 0.37) | 0.001   |
| C-reactive protein, mg/L, median (IQR)          | 68.6 (27.0, 139.5) | 64.9 (27.0, 134.3) | 76.1 (27.0, 156.0) | 0.008   |
| Preadmission medications, n (%)                 |                    |                    |                    |         |
| Nonstatin anticholesterol agent                 | 104 (7.6%)         | 78 (8.0%)          | 26 (6.8%)          | 0.46    |
| Renin-angiotensin-aldosterone system inhibitors | 684 (50.3%)        | 537 (54.9%)        | 147 (38.5%)        | < 0.001 |
| Beta blocker                                    | 687 (50.5%)        | 546 (55.8%)        | 141 (36.9%)        | < 0.001 |
| Antiplatelet agent                              | 812 (59.7%)        | 682 (69.7%)        | 130 (34.0%)        | < 0.001 |

0.57 to 0.99],  $p = 0.04$ ). However, in model 4, when troponin and CRP were also included, the association between preadmission statin use and the primary outcome was further attenuated and no longer significant (OR 0.83 [95% CI 0.63 to 1.09]  $p = 0.18$ ) (Figure 2). Unadjusted secondary outcomes appear in Table 3. Compared with those who were not taking statins before admission, preadmission statin use was associated with significant reduction in thrombotic complications and lengths of stay. In-hospital all-cause mortality and composite death or ICU admission occurred less frequently in those on preadmission statins, but these differences were not statistically significant.

## Discussion

In a retrospective analysis of patients with established atherosclerotic cardiovascular disease who were hospitalized with COVID-19, preadmission statin use was associated with a lower incidence of composite in-hospital death, ICU admission, or thrombotic complications. This association persisted despite sequentially adjusting for demographics, clinical characteristics, and other cardiovascular medications but became null after including baseline CRP and troponin levels, suggesting that the observed association between preadmission statin use and clinical outcome

Table 2

| Statin usage       |              |
|--------------------|--------------|
| Statin intensity*  |              |
| Low                | 91 (6.7%)    |
| Intermediate       | 409 (30.1%)  |
| High               | 506 (37.2%)  |
| Statin solubility† |              |
| Lipophilic         | 824 (84.3%)  |
| Hydrophilic        | 172 (17.6%)  |
| Statin agent       |              |
| Atorvastatin       | 675 (69.0 %) |
| Simvastatin        | 108 (11.0 %) |
| Pravastatin        | 87 (8.9 %)   |
| Rosuvastatin       | 68 (7.0 %)   |
| Lovastatin         | 39 (4 %)     |
| Pitavastatin       | 1 (0.1 %)    |

\* Classification of statin intensity by agent and dose is presented in Supplemental Material.

† Classification of statin lipophilicity by agent is presented in Supplemental Material.

may have been mediated, in part, by reductions in inflammation and/or myocardial injury.

Elevated troponin, even at low levels, portends a poorer outcome in patients with COVID-19. Even minor myocardial injury is associated with significant increase in mortality,<sup>12</sup> more severe respiratory illness, and greater likelihood of composite death, intubation, need for critical care, or cardiac arrest.<sup>13</sup> The pathophysiology underlying myocardial injury in patients with acute viral infection is multifactorial and may involve inflammatory, prothrombotic, and procoagulant cascades.<sup>4,14</sup> Markers of these pathways have been observed in high concentrations in patients with severe multisystem COVID-19 illness and “cytokine storm”.<sup>15</sup> The

activation of these cascades can also promote coronary plaque instability and acute thrombosis, resulting in type 1 MI.<sup>4</sup> Critical illness, sepsis, hypoxemia, acidosis, and hypotension may result in supply-demand mismatch and consequent type 2 MI.<sup>14,16</sup> Nonischemic myocardial injury may also result from direct injury to myocytes by SARS-CoV-2 through angiotensin-converting enzyme 2 receptors.<sup>17</sup> The ability of statin treatment to ameliorate myocardial injury has been established in other settings.<sup>18</sup>

Patients with COVID-19 and elevated inflammatory markers (i.e., hyperinflammatory response) have poorer outcome, including greater need for oxygen supplementation, mechanical ventilation, and extracorporeal membrane oxygenation and higher mortality than those in a hypoinflammatory response.<sup>15,19</sup> Dysregulation of angiotensin signaling resulting from SARS-COV-2 and angiotensin-converting enzyme 2 receptor interaction leads to proinflammatory cytokine release and promotes platelet activation, which in turn releases other proinflammatory factors, culminating in a cascade of inflammation and thrombosis.<sup>20</sup> It is possible that statin-driven benefits are linked to anti-inflammatory and immunomodulatory effects through lipid raft disruption; inhibition of the nuclear factor kappa-light-enhancer pathway; and suppression of cytokines, chemokines, and CRP.<sup>21,22</sup> In the Hydroxymethylglutaryl-CoA Reductase Inhibition with Simvastatin in Acute Lung Injury to Reduce Pulmonary Dysfunction-2 Study, simvastatin was associated with improved survival in the hyperinflammatory subphenotype of adult respiratory distress syndrome compared with placebo.<sup>23</sup>

There are conflicting data regarding the association between preadmission statin use and outcome in patients with COVID-19, although when meta-analyzed,




Figure 2. Forrest plot summarizing unadjusted and sequential multivariable logistic regression models. Demographic and clinical characteristics considered for inclusion in multivariable models were demographics (age, gender, ethnicity), clinical characteristics (smoking, obesity, hypertension, previous myocardial infarction, previous cerebrovascular disease, previous cardiac arrhythmias, pulmonary circulatory disorders, liver disease), cardiovascular medications ( $\beta$  blockers, renin-angiotensin-aldosterone system inhibitors, antiplatelets).

Table 3  
Secondary outcomes

| Outcome                                   | Total (n = 1360) | Statin therapy  |                 | P-value |
|---|------------------|-----------------|-----------------|---------|
|   |                  | Yes (n = 978)   | No (n = 382)    |         |
| Death                                     | 265 (19.5%)      | 183 (18.7%)     | 82 (21.5%)      | 0.25    |
| Death or admission to intensive care unit | 411 (30.2%)      | 281 (28.7%)     | 130 (34.0%)     | 0.06    |
| Composite thrombotic complications*       | 363 (26.7%)      | 235 (24.0%)     | 128 (33.5%)     | <0.001  |
| Stroke/TIA                                | 137 (10.1%)      | 83 (8.5%)       | 54 (14.1%)      | 0.001   |
| ACS                                       | 156 (11.5%)      | 101 (10.3%)     | 55 (14.4%)      | 0.034   |
| Acute DVT/PE                              | 98 (7.2%)        | 67 (6.9%)       | 31 (8.1%)       | 0.42    |
| Acute mesenteric ischemia                 | 2 (0.1%)         | 2 (0.2%)        | 0 (0.0%)        | 0.38    |
| Acute limb ischemia                       | 19 (1.4%)        | 12 (1.2%)       | 7 (1.8%)        | 0.39    |
| Length of stay, median (IQR)              | 6.0 (4.0, 13.0)  | 6.0 (4.0, 12.0) | 7.0 (4.0, 14.0) | 0.002   |

\* Composite thrombotic complications: myocardial infarction, ischemic cerebrovascular accident, venous thromboembolism, acute limb ischemia, and acute mesenteric ischemia.

ACS = acute coronary syndrome; MI = myocardial infarction; TIA = transient ischemic attack, DVT = deep venous thrombosis, PE = pulmonary embolism.

preadmission statin therapy is associated with more favorable outcomes.<sup>10</sup> Our results are congruent with these aggregated findings, and our observation that statins are associated with less myocardial injury and fewer thrombotic complications in this setting is novel. To our knowledge, our study is the first to account for markers of inflammation and myocardial injury in sequential multivariable logistic regression models and to suggest that the improved outcomes associated with upstream statin use in patients who were hospitalized with COVID-19 may be related to lesser degrees of myocardial injury and/or inflammation. This observation is biologically plausible, especially because data suggest early activation of thrombosis and inflammatory cascades with SARS-COV-2 infection.<sup>24,25</sup> In preliminary findings from the INSPIRATION-S study of critically ill patients with COVID-19, the composite outcome, arterial and venous thrombosis, use of extracorporeal membrane oxygenation, or 30-day death occurred numerically less often in atorvastatin than placebo-treated groups, but these differences were not statistically significant.<sup>26,27</sup> However, an interaction between treatment assignment and duration of symptoms was of marginal statistical significance, raising the possibility that treatment initiation closer to symptom onset (i.e., before admission) when inflammation is less pronounced might have conferred benefit. Given that the mean time from symptoms to hospitalization with COVID-19 is approximately 6 days,<sup>28</sup> and that statin-induced reductions in CRP and troponin are evident in 1 and 7 days,<sup>29</sup> respectively, initiation of statin therapy among naïve patients with COVID-19 could potentially translate into lower levels of inflammation and myocardial injury and reduce the likelihood of clinical deterioration. Although randomized trials are examining the role of statin therapy in patients with COVID-19, most have included patients only after they are hospitalized.<sup>21</sup> Only 1 small ongoing trial is evaluating upstream statin therapy in ambulatory patients with COVID-19, but that trial is designed to assess changes in viral load and CRP and is likely underpowered to identify statin-mediated differences in secondary clinical outcomes.<sup>30</sup>

There are noteworthy limitations to our study. First, by restricting our cohort to those with clinically manifest atherosclerotic vascular disease, we attempted to minimize the likelihood of confounding by indication; however, we

cannot exclude potential sources of residual confounding, despite multivariable modeling of the primary composite outcome. Second, we used International Classification of Diseases, Tenth Revision codes to define clinical outcomes; resultant, under-, or miscoding may have introduced inaccuracies in our data; although, if that were the case, it would likely have biased our results toward the null. Third, preadmission statin use was confirmed through medication reconciliation by patient report at the time of admission; pharmacy data, which indicated whether prescribed statins were dispensed or refilled, were not available. Fourth, our results may not be generalizable to the primary prevention setting. Finally, only in-hospital clinical outcomes were ascertained; whether preadmission statin use is associated with more favorable long-term outcomes after COVID-19 is unknown.

In conclusion, among patients with established atherosclerotic cardiovascular disease hospitalized with COVID-19, preadmission statin therapy was associated with improved in-hospital outcome; this association was no longer significant after markers of inflammation and myocardial injury were considered, suggesting that the observed association may be mediated through upstream suppression of these phenomena.

## Disclosures

The authors have no conflicts of interest to declare.

## Supplementary materials

Supplementary material associated with this article can be found in the online version at <https://doi.org/10.1016/j.amjcard.2022.04.045>.

1. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: a review. *JAMA Cardiol* 2020;5:831–840.
2. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu Z. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19) [published correction appears in *JAMA Cardiol* 2020 Jul 1;5:848] *JAMA Cardiol* 2020;5:811–818.

3. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q, Huang H, Yang B, Huang C. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. *JAMA Cardiol* 2020;5:802–810.
4. Sandoval Y, Januzzi JL Jr, Jaffe AS. Cardiac troponin for assessment of myocardial injury in COVID-19: JACC review topic of the week. *J Am Coll Cardiol* 2020;76:1244–1258.
5. Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system [published correction appears in *Circ Res* 2018;123:e20] *Circ Res* 2017;120:229–243.
6. Bodde MC, Welsh P, Bergheanu SC, Lijfering WM, Mertens B, Liem AH, van der Laarse A, Sattar N, Jukema JW. Rapid. A rapid (differential) effect of rosuvastatin and atorvastatin on high-sensitivity cardiac troponin-I in subjects with stable cardiovascular disease. *Clin Pharmacol Ther* 2018;104:311–316.
7. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhalra N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet* 2010;376:1670–1681.
8. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. *JAMA* 2001;285:1711–1718.
9. Gupta A, Madhavan MV, Poterucha TJ, DeFilippis EM, Hennessey JA, Redfors B, Eckhardt C, Bickdeli B, Platt J, Nalbandian A, Elias P, Cummings MJ, Nouri SN, Lawlor M, Ranard LS, Li J, Boyle C, Givens R, Brodie D, Krumholz HM, Stone GW, Sethi SS, Burkhoff D, Uriel N, Schwartz A, Leon MB, Kirtane AJ, Wan EY, Parikh SA. Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. *Nat Commun* 2021;12:1325.
10. Diaz-Arocutipa C, Melgar-Talavera B, Alvarado-Yarasca A, Saravia-Bartra MM, Cazorla P, Belzusarri I, Hernandez AV. Statins reduce mortality in patients with COVID-19: an updated meta-analysis of 147 824 patients. *Int J Infect Dis* 2021;110:374–381.
11. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2014;63(25 Pt B):2889–2934.
12. Lala A, Johnson KW, Januzzi JL, Russak AJ, Paranjpe I, Richter F, Zhao S, Somani S, Van Vleck T, Vaid A, Chaudhry F, De Freitas JK, Fayad ZA, Pinney SP, Levin M, Charney A, Bagiella E, Narula J, Glicksberg BS, Nadkarni G, Mancini DM, Fuster V, Center Mount Sinai COVID Informatics. Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. *J Am Coll Cardiol* 2020;76:533–546.
13. Singh N, Anchan RK, Besser SA, Belkin MN, Cruz MD, Lee L, Yu D, Mehta N, Nguyen AB, Alenghat FJ. High sensitivity troponin-T for prediction of adverse events in patients with COVID-19. *Biomarkers* 2020;25:626–633.
14. Musher DM, Abers MS, Corrales-Medina VF. Acute infection and myocardial infarction. *N Engl J Med* 2019;380:171–176.
15. Izcovich A, Ragusa MA, Tortosa F, Lavena Marzio MA, Agnoletti C, Bengolea A, Ceirano A, Espinosa F, Saavedra E, Sanguine V, Tassara A, Cid C, Catalano HN, Agarwal A, Foroutan F, Rada G. Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. *PLoS One* 2020;15:e0241955.
16. Sandoval Y, Jaffe AS. Type 2 myocardial infarction: JACC review topic of the week. *J Am Coll Cardiol* 2019;73:1846–1860.
17. Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. *Cardiovasc Res* 2020;116:1097–1100.
18. Ford I, Shah AS, Zhang R, McAllister DA, Strachan FE, Caslake M, Newby DE, Packard CJ, Mills NL. High-sensitivity cardiac troponin, statin therapy, and risk of coronary heart disease. *J Am Coll Cardiol* 2016;68:2719–2728.
19. Lee EE, Song KH, Hwang W, Ham SY, Jeong H, Kim JH, Oh HS, Kang YM, Lee EB, Kim NJ, Chin BS, Park JK. Pattern of inflammatory immune response determines the clinical course and outcome of COVID-19: unbiased clustering analysis. *Sci Rep* 2021;11:8080.
20. Sriram K, Insel PA. Inflammation and thrombosis in covid-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets. *Physiol Rev* 2021;101:545–567.
21. Talasz AH, Sadeghipour P, Aghakouchakzadeh M, Dreyfus I, Kakavand H, Ariannejad H, Gupta A, Madhavan MV, Van Tassel BW, Jimenez D, Monreal M, Vaduganathan M, Fanikos J, Dixon DL, Piazza G, Parikh SA, Bhatt DL, Lip GYH, Stone GW, Krumholz HM, Libby P, Goldhaber SZ, Bickdeli B. Investigating lipid-modulating agents for prevention or treatment of COVID-19: JACC state-of-the-art review. *J Am Coll Cardiol* 2021;78:1635–1654.
22. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med* 2008;359:2195–2207.
23. Calfee CS, Delucchi KL, Sinha P, Matthay MA, Hackett J, Shankar-Hari M, McDowell C, Laffey JG, O'Kane CM, McAuley DF. Irish Critical Care Trials Group. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. *Lancet Respir Med* 2018;6:691–698.
24. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, Kucher N, Studt JD, Sacco C, Bertuzzi A, Sandri MT, Barco S. Humanitas COVID-19 Task Force. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. *Thromb Res* 2020;191:9–14.
25. Tan C, Huang Y, Shi F, Tan K, Ma Q, Chen Y, Jiang X, Li X. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. *J Med Virol* 2020;92:856–862.
26. Bickdeli B, Talasz AH, Rashidi F, Sharif-Kashani B, Farrokhpour M, Bakhshandeh H, Sezavar H, Dabbagh A, Beigmohammadi MT, Payandemehr P, Yadollahzadeh M, Riahi T, Khalili H, Jamalkhani S, Rezaeifar P, Abedini A, Lookzadeh S, Shahmirzaei S, Tahamtan O, Matin S, Amin A, Parhizgar SE, Jimenez D, Gupta A, Madhavan MV, Parikh SA, Monreal M, Hadavand N, Hajighasemi A, Maleki M, Sadeghian S, Mohebbi B, Piazza G, Kirtane AJ, Lip GYH, Krumholz HM, Goldhaber SZ, Sadeghipour P. Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: rationale and design of the INSPIRATION/INSPIRATION-S studies. *Thromb Res* 2020;196:382–394.
27. American College of Cardiology. ACC.21 presentation slides | INSPIRATION-S. Available at: <https://www.acc.org/education-and-meetings/image-and-slide-gallery/media-detail?id=9DF17809F35C4-CA6B149C64C9D700AC6>. Accessed on May 22, 2021.
28. Quaresima V, Scarpazza C, Sottini A, Fiorini C, Signorini S, Delmonte OM, Signorini L, Quiros-Roldan E, Imberti L. Sex differences in a cohort of COVID-19 Italian patients hospitalized during the first and second pandemic waves [published correction appears in *Biol Sex Differ* 2021;12:48] *Biol Sex Differ* 2021;12:45.
29. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Scascio G, ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. *Circulation* 2004;110:674–678.
30. ClinicalTrials.gov. Combination therapies to reduce carriage of SARS-Cov-2 and improve outcome of COVID-19 in Ivory Coast: a phase randomized IIB trial (INTENSE-COV). Available at: <https://clinicaltrials.gov/ct2/show/NCT04466241>. Accessed on November 13, 2021.